Please assess the completion status of the following clinical trial:

Trial Title: A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Active Multiple Myeloma Stage II or III Durie Salmon~* Measurable levels of myeloma paraprotein in serum (≥1.0g/dL) or urine (≥ 0.2g excreted in a 24-hour collection sample)~* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, 2~* Women of child bearing potential must agree to abstain for heterosexual intercourse or use 2 methods of contraception, one effective (for example hormonal or tubal ligation) and one barrier (for example latex condom, diaphragm)~* Males must agree to use barrier contraception (latex condoms) when engaging in reproductive activity~Exclusion Criteria:~* Pregnant or lactating females~* Peripheral neuropathy ≥ to grade 2 of the NCI CTC.~* Prior history of malignancy unless subject has been free of disease for ≥ 3 years~* Lab abnormality: Absolute neutrophil count (ANC) \<1,000 cells/mm\^3 (1.0 x 10\^9/L)~* Lab abnormality: Platelet count \<50,000/mm\^3 (50.0 x 10\^9/L)~* Lab abnormality: Serum creatinine \>3.0 mg/dL (265 µmol/L)~* Lab abnormality: Serum glutamic oxaloacetic transaminase (SGOT) /Aspartate aminotransferase (AST) or Serum glutamic pyruvic transaminase (SGPT)/Alanine transaminase (ALT) \>3.0 x upper limit of normal (ULN)~* Lab abnormality: Serum total bilirubin \> 2.0 mg/dL (34 µmol/L)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Thalidomide & Dexamethasone) (Type: EXPERIMENTAL): Thalidomide 50mg/day + Dexamethasone 40mg
- B (Dexamethasone and placebo) (Type: PLACEBO_COMPARATOR): Dexamethasone and placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).